Ticker
ABVC

Price
0.70
Stock movement down
-0.01 (-0.97%)
Company name
ABVC Biopharma Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
22.94M
Ent value
26.41M
Price/Sales
66.89
Price/Book
4.03
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-72.64%
3 year return
-53.06%
5 year return
-87.78%
10 year return
-
Last updated: 2023-02-03

DIVIDENDS

ABVC does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales66.89
Price to Book4.03
EV to Sales76.99

FINANCIALS

Per share

Loading...
Per share data
Current share count32.63M
EPS (TTM)-0.60
FCF per share (TTM)-0.28

Income statement

Loading...
Income statement data
Revenue (TTM)343.00K
Gross profit (TTM)319.19K
Operating income (TTM)-18.43M
Net income (TTM)-19.49M
EPS (TTM)-0.60
EPS (1y forward)-0.36

Margins

Loading...
Margins data
Gross margin (TTM)93.06%
Operating margin (TTM)-5372.83%
Profit margin (TTM)-5682.74%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.32M
Net receivables547.68K
Total current assets2.90M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets10.48M
Accounts payable0.00
Short/Current long term debt3.11M
Total current liabilities3.89M
Total liabilities4.79M
Shareholder's equity5.69M
Net tangible assets5.92M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-8.99M
Capital expenditures (TTM)212.82K
Free cash flow (TTM)-9.02M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-342.37%
Return on Assets-185.98%
Return on Invested Capital-246.01%
Cash Return on Invested Capital-113.84%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.72
Daily high0.74
Daily low0.70
Daily Volume70K
All-time high716331.21
1y analyst estimate9.50
Beta0.28
EPS (TTM)-0.60
Dividend per share-
Ex-div date-
Next earnings date29 Mar 2023

Downside potential

Loading...
Downside potential data
ABVCS&P500
Current price drop from All-time high-100.00%-13.68%
Highest price drop-100.00%-56.47%
Date of highest drop3 Feb 20239 Mar 2009
Avg drop from high-91.23%-11.49%
Avg time to new high119 days13 days
Max time to new high1728 days1805 days
COMPANY DETAILS
ABVC (ABVC Biopharma Inc) company logo
Marketcap
22.94M
Marketcap category
Small-cap
Description
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Employees
28
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
January 19, 2023
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Several potential paths to near-term milestones… ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies fo...
January 18, 2023
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
January 5, 2023
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Adding venues and enrolling patients to advance assets … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing ther...
December 20, 2022
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
November 17, 2022
ABVC BioPharma ( NASDAQ:ABVC ) Third Quarter 2022 Results Key Financial Results Net loss: US$3.70m (loss widened by...
November 17, 2022
FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
November 14, 2022
FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
November 7, 2022
FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
November 2, 2022
FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
October 5, 2022
Next page